Evidence map›Paper›PMID 37103108›Full record

ReviewIn vivo (Athens, Greece)

Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.

Moriyasu Yamauchi, Akimichi Minesaki, Tomoya Ishida, Yuki Sato, Seiji Okamura, Hiroyuki Shuto, Nariyuki Tanaka, Eriko Hatayama, Natsuko Shibamiya, Yuichiro Kuratomi

Open access · diamondAbstract readReview
In one paragraph

Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Moriyasu YamauchiDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan yamamori@cc.saga-u.ac.jp.ORCID https://orcid.org/0000-0002-7719-4187
Akimichi MinesakiDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Tomoya IshidaDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Yuki SatoDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Seiji OkamuraDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Hiroyuki ShutoDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Nariyuki TanakaDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Eriko HatayamaDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Natsuko ShibamiyaDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Yuichiro KuratomiDepartment of Otolaryngology - Head & Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
Saga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimChemoradiotherapy (CRT) with high-dose cisplatin has become the standard of care for larynx preservation in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, the long-term results are unsatisfactory. Induction chemotherapy (ICT) with docetaxel/cisplatin/5-fluorouracil (TPF) is associated with hematologic toxicity, and a safer therapy with comparable efficacy is desired. We conducted a pilot study to investigate the efficacy and safety of 5-fluorouracil/cisplatin/cetuximab (FPE) therapy as a candidate regimen for ICT in comparison with TPF. PATIENTS AND

methodsPatients with stage cN2/3 LA-SCCHN of the larynx/oropharynx/hypopharynx were treated with FPE or TPF followed by radiotherapy. We reviewed patients' medical records and evaluated treatment efficacy and safety retrospectively.

resultsThe response rates for ICT and ICT-radiotherapy were 71% and 93%, respectively, in the FPE group and 90% and 89%, respectively, in the TPF group. The 1-year progression-free and overall survival rates were 57% and 100%, respectively, in the FPE group and 70% and 90%, respectively, in the TPF group. TPF was linked to significantly higher rates of Grade 3/4 hematologic toxicity during ICT. The rates of Grade 3 or higher toxicity did not differ between the two groups during radiotherapy.

conclusionThe efficacy of ICT was comparable between the FPE and TPF groups, whereas FPE was associated with less toxicity. It is suggested that FPE therapy is an alternative ICT regimen to TPF therapy, but further long-term follow-up is needed.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCetuximabChemoradiotherapyCisplatinDocetaxelFluorouracilHumansInduction ChemotherapyPilot ProjectsRetrospective StudiesSquamous Cell Carcinoma of Head and NeckTaxoidsCetuximabCisplatinDocetaxelFluorouracilTaxoidscetuximabhead and neck cancerInduction chemotherapylarynx preservationsquamous cell carcinoma

Identifiers

PMID37103108
PMCPMC10188000
OpenAlexW4367173986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.